ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.

被引：0
|
作者：
Ghazaly, Essam Ahmed
Joel, Simon
Gribben, John G.
Mohammad, Tariq
Emiloju, Oluwadunni
Stavraka, Chara
Hopkins, Tom
Gabra, Hani
Wasan, Harpreet
Habib, Nagy A.
Leonard, Robert C. F.
McGuigan, Christopher
Slusarczyk, Magdalena
Blagden, Sarah Patricia
机构：
[1] Queen Mary Univ London, Barts Canc Inst, London, England
[2] Univ London Imperial Coll Sci Technol & Med, NIHR Wellcome Trust Imperial Clin Res Facil, London, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London, England
[4] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff CF10 3AX, S Glam, Wales
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2576
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.
    Shimizu, Toshio
    Yonemori, Kan
    Koyama, Takafumi
    Katsuya, Yuki
    Sato, Jun
    Fukuhara, Noriko
    Yokoyama, Hisayuki
    Iida, Hiroatsu
    Ando, Koji
    Fukuhara, Suguru
    Miyake, Hiroshi
    Tanoue, Yasushi
    Tozaki, Hirokazu
    Mizutani, Akio
    Morishita, Daisuke
    Takeyama, Kunihiko
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors.
    Mahalingam, Devalingam
    Shaheen, Montaser F.
    Sarantopoulos, John
    Weitman, Steven
    Giovanella, Beppino C.
    Cao, Zhisong
    Coil, Douglas
    Markides, Constantine
    Liu, Lucy
    Verschraegen, Claire F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.
    Gallagher, Peter F.
    Naylor, Gregory
    Bashir, Saira
    Yan, Xiangfei
    Burke, David
    Plummer, Elizabeth Ruth
    Evans, T. R. Jeffry
    Coyle, Victoria M.
    Clive, Sally
    McGuigan, Lesley
    Heinzmann, Kathrin
    Halbert, Gavin
    Veal, Gareth
    Tiplady, Eleanor
    Barnett, Shelby
    Yalla, Krishna
    Brook, Sue
    Dobbs, Nicola
    Wilson, Richard H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
    Elena Elez, Maria
    Tabernero, Josep
    Geary, David
    Macarulla, Teresa
    Kang, S. Peter
    Kahatt, Carmen
    Soto-Matos Pita, Arturo
    Fernandez Teruel, Carlos
    Siguero, Mariano
    Cullell-Young, Martin
    Szyldergemajn, Sergio
    Ratain, Mark J.
    CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2205 - 2214
  • [25] A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
    Koganemaru, S.
    Yoshizuka, N.
    Mizuno, S.
    Hirai, S.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S531 - S531
  • [26] A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.
    McKean, Meredith
    Hutson, Thomas E.
    Piha-Paul, Sarina A.
    Micaily, Ida
    Liao, Mingxiang
    Humphreys, Robin
    Brock, Graham
    Sahr, Natasha
    Amber, Vian
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors.
    Johnson, Melissa
    Ulahannan, Susanna
    Vandross, Andrae
    Park, Haeseong
    Faoro, Leo
    Faggioni, Raffaella
    Li, Jing
    Chang, Yu-Lin
    Uttamsingh, Shailaja
    Tolcher, Anthony
    CANCER RESEARCH, 2022, 82 (12)
  • [28] Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors.
    Powderly, John
    Shimizu, Toshio
    LoRusso, Patricia
    Razak, Albiruni
    Miller, Kathy
    Balar, Arjun
    Bruix, Jordi
    Michel, Loren
    Blaney, Martha
    Guan, Xiaowen
    Lacy, Susan
    Lally, Satwant
    Lambert, Stacie
    Leibman, Rachel
    Vosganian, Gregory
    Golan, Talia
    Tolcher, Anthony
    CANCER RESEARCH, 2021, 81 (13)
  • [29] First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors.
    Matsubara, Nobuaki
    Shitara, Kohei
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ohno, Izumi
    Takahashi, Hideaki
    Bando, Hideaki
    Kojima, Takashi
    Fuse, Nozomu
    Yamazaki, Tomoko
    Hirayama, Naoki
    Fujita, Hidenori
    Nishida, Toshirou
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Liang, Yan
    Harvey, R. Donald
    Fu, Siqing
    Weitao, Yao
    Qin, Yan-Ru
    Zhang, Xiaojing
    Henry, Jason Timothy
    Zou, Qingping
    Shan, Boyao
    Liang, Pan
    Wang, Chen
    Li, Wenjia
    Pamuklar, Zehra Nurgul
    Pei, Yi
    Chang, Zhiwei
    Wang, Jiaqiang
    Piha-Paul, Sarina A.
    Bhave, Manali A.
    Yin, Yongmei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345